Skip to content
← All treatment topics

TREATMENT READING

Esophageal Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

42 sections
  1. Treatment Option Overview for Esophageal Cancer
  2. Surgery
  3. Surgery (Barrett esophagus)
  4. Surgery (esophageal cancer)
  5. Preoperative Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy and/or Immunotherapy
  6. Fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy plus trastuzumab and pertuzumab
  7. Preoperative Chemoradiation Therapy
  8. Preoperative Chemotherapy
  9. Perioperative Chemotherapy
  10. Definitive Chemoradiation Therapy
  11. Adjuvant Therapy
  12. Immunotherapy and Chemoimmunotherapy
  13. Immunotherapy and chemoimmunotherapy for patients with squamous cell carcinoma
  14. Immunotherapy and chemoimmunotherapy for patients with adenocarcinoma
  15. Immunotherapy for patients who relapse after one prior line of standard therapy
  16. Postoperative Radiation Therapy
  17. Capecitabine and Fluorouracil Dosing
  18. Treatment of Stage 0 Esophageal Cancer
  19. Treatment Options for Stage 0 Esophageal Cancer
  20. Treatment of Stage I Esophageal Cancer
  21. Treatment Options for Stage I Esophageal Cancer
  22. Treatment of Stage II Esophageal Cancer
  23. Treatment Options for Stage II Esophageal Cancer
  24. Treatment of Stage III Esophageal Cancer
  25. Treatment Options for Stage III Esophageal Cancer
  26. Treatment of Stage IV Esophageal Cancer
  27. Treatment Options for Stage IV Esophageal Cancer
  28. Treatment of Recurrent Esophageal Cancer
  29. Treatment Options for Recurrent Esophageal Cancer
  30. Esophageal Cancer Treatment
  31. Surgery
  32. Radiation therapy
  33. Chemotherapy
  34. Chemoradiation therapy
  35. Laser therapy
  36. Electrocoagulation
  37. Immunotherapy
  38. New treatments being tested in clinical trials
  39. Targeted therapy
  40. Clinical trials
  41. Side effects of treatment
  42. Follow-up care

Health professional

Treatment Option Overview for Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

For patients with minimally invasive resectable esophageal cancer, surgical resection alone offers the potential for cure. In contrast, therapeutic management for patients with locally advanced resectable esophageal cancer has evolved significantly over the last few decades. Because of the risk of distant metastases and local relapse, multimodality therapy with chemotherapy, radiation therapy, and surgical resection has become the standard of care.

The following combinations may provide effective palliation in individual cases:

Surgery.

Chemotherapy.

Radiation therapy.

Stents, photodynamic therapy, and endoscopic therapy with Nd:YAG laser. Self-expandable metal stent positioning is the recommended method for palliation of dysphagia from esophageal cancer.[1-6]

Sources: 1 · 6

Table 12. Treatment Options for Esophageal Cancer
Stage (TNM Staging Criteria)Treatment Options
Stage 0 Esophageal CancerSurgery
Endoscopic resection
Stage I Esophageal CancerChemoradiation therapy followed by surgery
Surgery alone
Stage II Esophageal CancerChemoradiation therapy followed by surgery
Surgery alone
Chemotherapy followed by surgery
Definitive chemoradiation therapy
Stage III Esophageal CancerChemoradiation therapy followed by surgery
Preoperative chemotherapy followed by surgery
Definitive chemoradiation therapy
Stage IV Esophageal CancerChemoradiation therapy followed by surgery (for patients with stage IVA disease)
Chemotherapy, which has provided partial responses for patients with metastatic distal esophageal adenocarcinomas
Adjuvant therapy for patients with completely resected (negative margins) esophageal adenocarcinoma, esophageal squamous cell carcinoma, or gastroesophageal junction cancer who had residual pathological disease after concurrent chemoradiation therapy
Immunotherapy and chemoimmunotherapy for patients with previously untreated, unresectable, advanced or metastatic esophageal squamous cell carcinoma
Immunotherapy and chemoimmunotherapy for patients with previously untreated advanced or metastatic esophageal adenocarcinoma or gastroesophageal junction cancer
Immunotherapy for patients who relapse after one prior line of standard therapy
Nivolumab and chemotherapy for patients with adenocarcinoma
Nd:YAG endoluminal tumor destruction or electrocoagulation
Endoscopic-placed stents to provide palliation of dysphagia
Radiation therapy with or without intraluminal intubation and dilation
Intraluminal brachytherapy to provide palliation of dysphagia
Clinical trials evaluating single-agent or combination chemotherapy
Recurrent Esophageal CancerPalliative use of any of the other therapies, including supportive care
Immunotherapy and chemoimmunotherapy for patients with recurrent esophageal squamous cell carcinoma

Sources: TNM Staging Criteria · Stage 0 Esophageal Cancer · Stage I Esophageal Cancer · Stage II Esophageal Cancer · Stage III Esophageal Cancer · Stage IV Esophageal Cancer · Recurrent Esophageal Cancer

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Esophageal Cancer

Surgery

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Esophageal Cancer / Surgery

Surgery (Barrett esophagus)

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

The prevalence of Barrett metaplasia in adenocarcinoma of the esophagus suggests that Barrett esophagus is a premalignant condition. Endoscopic surveillance of patients with Barrett metaplasia may detect adenocarcinoma at an earlier stage that is more amenable to curative resection. Strong consideration should be given to resection in patients with high-grade dysplasia in the setting of Barrett metaplasia.[7]

Sources: 7

Health professional · Treatment Option Overview for Esophageal Cancer / Surgery

Surgery (esophageal cancer)

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

The survival rate of patients with esophageal cancer is poor. Surgical treatment of resectable esophageal cancers results in 5-year survival rates of 5% to 30%, with higher survival rates in patients with early-stage cancers.[8] Asymptomatic small tumors confined to the esophageal mucosa or submucosa are detected only by chance. Surgery is the treatment of choice for these small tumors. Once symptoms are present (e.g., dysphagia, in most cases), esophageal cancers have usually invaded the muscularis propria or beyond and may have metastasized to lymph nodes or other organs.

Sources: 8

In some patients with partial esophageal obstruction, dysphagia may be relieved by placement of an expandable metallic stent [9] or by radiation therapy if the patient has disseminated disease or is not a candidate for surgery. Alternative methods of relieving dysphagia have been reported, including laser therapy and electrocoagulation to destroy intraluminal tumor.[10-12]

Sources: 9 · 10 · 12

In the presence of complete esophageal obstruction without clinical evidence of systemic metastasis, surgical excision of the tumor with mobilization of the stomach to replace the esophagus has been the traditional means of relieving the dysphagia.

The optimal surgical approach for radical resection of esophageal cancer is not known. One approach advocates transhiatal esophagectomy with anastomosis of the stomach to the cervical esophagus. A second approach advocates abdominal mobilization of the stomach and transthoracic excision of the esophagus with anastomosis of the stomach to the upper thoracic esophagus or the cervical esophagus. One study concluded that transhiatal esophagectomy was associated with lower morbidity than was transthoracic esophagectomy with extended en bloc lymphadenectomy; however, median overall disease-free and quality-adjusted survival did not differ significantly.[13] Similarly, no differences in long-term quality of life (QOL) using validated QOL instruments have been reported.[14] More recently, minimally invasive approaches that offer potential advantages of smaller incisions, decreased intraoperative blood loss, fewer postoperative complications, and shorter hospital stays have emerged. However, the ability to obtain negative surgical margins, the adequacy of lymph node dissection, and long-term outcomes have not been fully established with this approach.[15]

Sources: 13 · 14 · 15

In the United States, the median age of patients who present with esophageal cancer is 68 years.[16] The results of a retrospective review of 505 consecutive patients who were operated on by a single surgical team over 17 years found no difference in the perioperative mortality, median survival, or palliative benefit of esophagectomy on dysphagia when the patients older than 70 years were compared with their younger peers.[17][Level of evidence C1] All of the patients in this series were selected for surgery on the basis of potential operative risk. Age alone does not determine therapy for patients with potentially resectable disease.

Sources: 16 · 17 · Level of evidence C1

Health professional · Treatment Option Overview for Esophageal Cancer

Preoperative Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy and/or Immunotherapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Esophageal Cancer / Preoperative Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy and/or Immunotherapy

Fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy plus trastuzumab and pertuzumab

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Evidence (fluorouracil [5-FU], leucovorin, oxaliplatin, and docetaxel [FLOT] chemotherapy plus trastuzumab and pertuzumab):

A multicenter phase II/III trial (NCT02581462) included patients with human epidermal growth factor receptor 2 (HER2)-positive resectable gastric or gastroesophageal junction adenocarcinoma (clinical T2 or larger or clinically node-positive). A total of 81 patients (61 with gastroesophageal cancer, 20 with gastric cancer) were enrolled during the phase II part of the study. Patients were randomly assigned to receive four preoperative and postoperative cycles of either FLOT alone (arm A, n = 41) or FLOT combined with trastuzumab and pertuzumab followed by nine cycles of trastuzumab and pertuzumab (arm B, n = 40). In the phase II part of the study, the primary end point was the rate of pathological complete response. The trial did not transition to phase III. It closed prematurely, after results of the JACOB trial were reported, which demonstrated that adding pertuzumab to trastuzumab and chemotherapy did not significantly improve overall survival (OS) in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer compared with placebo.[18]

Sources: NCT02581462 · 18

A multicenter phase II/III trial (NCT02581462) included patients with human epidermal growth factor receptor 2 (HER2)-positive resectable gastric or gastroesophageal junction adenocarcinoma (clinical T2 or larger or clinically node-positive). A total of 81 patients (61 with gastroesophageal cancer, 20 with gastric cancer) were enrolled during the phase II part of the study. Patients were randomly assigned to receive four preoperative and postoperative cycles of either FLOT alone (arm A, n = 41) or FLOT combined with trastuzumab and pertuzumab followed by nine cycles of trastuzumab and pertuzumab (arm B, n = 40). In the phase II part of the study, the primary end point was the rate of pathological complete response. The trial did not transition to phase III. It closed prematurely, after results of the JACOB trial were reported, which demonstrated that adding pertuzumab to trastuzumab and chemotherapy did not significantly improve overall survival (OS) in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer compared with placebo.[18]

The pathological complete response rate was significantly improved for patients in arm B at 35%, compared with 12% for patients in arm A (P = .02).[18][Level of evidence B3]

Sources: 18 · Level of evidence B3

The rate of pathological lymph node negativity was higher for patients who received trastuzumab and pertuzumab (39% for arm A vs. 68% for arm B).

The R0 resection rate was 90% for patients in arm A and 93% for patients in arm B. Surgical morbidity was also comparable, at 43% for patients in arm A and 44% for patients in arm B.

The median disease-free survival (DFS) was 26 months for patients in arm A and not yet reached for patients in arm B (hazard ratio [HR], 0.58; P =.14).

The 24-month DFS rates were 54% (95% confidence interval [CI], 38%–71%) in arm A and 70% (95% CI, 55%–85%) in arm B. The 24-month OS rates were 77% (95% CI, 63%–90%) in arm A and 84% (95% CI, 72%–96%) in arm B.

More grade 3 or greater adverse events were reported among patients who received trastuzumab and pertuzumab, especially diarrhea (5% of patients in arm A and 41% of patients in arm B) and leukopenia (13% of patients in arm A and 23% of patients in arm B).

Health professional · Treatment Option Overview for Esophageal Cancer

Preoperative Chemoradiation Therapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

On the basis of several randomized trial results, chemoradiation followed by surgery is a treatment option for patients with stages IB, II, III, and IVA esophageal cancer.

Phase III trials have compared preoperative concurrent chemoradiation therapy with surgery alone for patients with esophageal cancer.[19-25][Level of evidence A1] The benefit of neoadjuvant chemoradiation has been controversial because of contradictory results of early randomized studies.[19-22] However, the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) has definitively demonstrated a survival benefit for preoperative chemoradiation compared with surgery alone in locally advanced esophageal cancer.[23]

Sources: 19 · 25 · Level of evidence A1 · 19 · 22 · 23

For early-stage tumors, the role of preoperative chemoradiation remains controversial. Although the CROSS study included early-stage patients, the Francophone de Cancérologie Digestive (FFCD) 9901 study (NCT00047112),[25] which included only early-stage (stage I or II) patients, failed to demonstrate a survival advantage in this group of patients.

Sources: NCT00047112 · 25

Evidence (preoperative chemoradiation therapy):

The CROSS study randomly assigned 366 patients with resectable esophageal or junctional cancers to receive either surgery alone or weekly administration of carboplatin (dose titrated to achieve an AUC [area under the curve] of 2 mg/mL/minute) and paclitaxel (50 mg/m2 of BSA [body surface area]) and concurrent radiation therapy (41.4 Gy in 23 fractions) administered over 5 weeks. Most patients enrolled in the CROSS trial (75%) had adenocarcinoma.[23,26][Level of evidence A1]

Sources: 23 · 26 · Level of evidence A1

The CROSS study randomly assigned 366 patients with resectable esophageal or junctional cancers to receive either surgery alone or weekly administration of carboplatin (dose titrated to achieve an AUC [area under the curve] of 2 mg/mL/minute) and paclitaxel (50 mg/m2 of BSA [body surface area]) and concurrent radiation therapy (41.4 Gy in 23 fractions) administered over 5 weeks. Most patients enrolled in the CROSS trial (75%) had adenocarcinoma.[23,26][Level of evidence A1]

With a median follow-up of 84 months, preoperative chemoradiation was found to improve median OS from 24 months in the surgery-alone group to 48.6 months (HR, 0.68; 95% CI, 0.53–0.88; P = .003). Median OS for patients with squamous cell carcinomas was 81.6 months in the preoperative chemoradiation group, compared with 21.1 months in the surgery-alone group (HR, 0.48; 95% CI, 0.28–0.83; log-rank P = .008); for patients with adenocarcinomas, median OS was 43.2 months in the preoperative chemoradiation group, compared with 27.1 months in the surgery-alone group (HR, 0.73; 95% CI, 0.55–0.98; log-rank P = .038).[26]

Sources: 26

Additionally, preoperative chemoradiation improved the rate of R0 resections (92% vs. 69%; P < .001). R0 is defined as complete resection with no tumor within 1 mm of resection margins.

A complete pathological response was achieved in 29% of patients who underwent resection after chemoradiation therapy. A pathological complete response was observed in 23% of patients with adenocarcinoma, compared with 49% of patients with squamous cell carcinoma (P = .008).

Postoperative complications and in-hospital mortality were equivalent in both groups. The most common hematologic side effects in the chemoradiation group were leukopenia (6%) and neutropenia (2%). The most common nonhematologic side effects were anorexia (5%) and fatigue (3%).

With a median follow-up of 84 months, the 5-year progression-free survival (PFS) rate was 44% in the preoperative chemoradiation group, compared with 27% in the surgery-alone group (HR, 0.61; 95% CI, 0.47–0.78). Preoperative chemoradiation therapy reduced locoregional recurrence from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001). There was a small but significant effect on hematogenous dissemination in favor of the chemoradiation therapy group (35% vs. 29%; P = .025).[24,26][Level of evidence B1]

Sources: 24 · 26 · Level of evidence B1

A multicenter, prospective, randomized trial compared preoperative combined chemotherapy (i.e., cisplatin) and radiation therapy (37 Gy in 3.7-Gy fractions) versus surgery alone in patients with squamous cell carcinoma.[19][Level of evidence A1]

Sources: 19 · Level of evidence A1

A multicenter, prospective, randomized trial compared preoperative combined chemotherapy (i.e., cisplatin) and radiation therapy (37 Gy in 3.7-Gy fractions) versus surgery alone in patients with squamous cell carcinoma.[19][Level of evidence A1]

The study showed no improvement in OS and a significantly higher postoperative mortality rate (12% vs. 4%) in the combined-modality arm.

In patients with adenocarcinoma of the esophagus, a single-institution phase III trial was conducted in patients treated with induction chemoradiation therapy consisting of 5-FU, cisplatin, and 40 Gy (in 2.67-Gy fractions) plus surgery compared with resection alone.[20][Level of evidence A1]

Sources: 20 · Level of evidence A1

In patients with adenocarcinoma of the esophagus, a single-institution phase III trial was conducted in patients treated with induction chemoradiation therapy consisting of 5-FU, cisplatin, and 40 Gy (in 2.67-Gy fractions) plus surgery compared with resection alone.[20][Level of evidence A1]

The results demonstrated a modest survival benefit of 16 months for combined modality therapy versus 11 months for surgery alone.

A subsequent single-institution trial randomly assigned patients (75% with adenocarcinoma) to 5-FU, cisplatin, vinblastine, and radiation therapy (1.5 Gy twice daily to a total of 45 Gy) plus resection versus esophagectomy alone.[21][Level of evidence A1]

Sources: 21 · Level of evidence A1

A subsequent single-institution trial randomly assigned patients (75% with adenocarcinoma) to 5-FU, cisplatin, vinblastine, and radiation therapy (1.5 Gy twice daily to a total of 45 Gy) plus resection versus esophagectomy alone.[21][Level of evidence A1]

At a median follow-up of more than 8 years, there was no significant difference between the surgery alone and combined modality therapy with respect to median survival (17.6 months vs. 16.9 months), OS rate (16% vs. 30% at 3 years), or DFS rate (16% vs. 28% at 3 years).

An intergroup trial (CALGB-9781 [NCT00003118]) planned to randomly assign 475 patients with resectable squamous cell or adenocarcinoma of the thoracic esophagus to treatment with preoperative chemoradiation therapy (5-FU, cisplatin, and 50.4 Gy) followed by esophagectomy and nodal dissection or surgery alone. The trial was closed as a result of poor patient accrual; however, results from the 56 enrolled patients, with a median follow-up of 6 years, were reported.[22][Level of evidence A1]

Sources: CALGB-9781 · 22 · Level of evidence A1

An intergroup trial (CALGB-9781 [NCT00003118]) planned to randomly assign 475 patients with resectable squamous cell or adenocarcinoma of the thoracic esophagus to treatment with preoperative chemoradiation therapy (5-FU, cisplatin, and 50.4 Gy) followed by esophagectomy and nodal dissection or surgery alone. The trial was closed as a result of poor patient accrual; however, results from the 56 enrolled patients, with a median follow-up of 6 years, were reported.[22][Level of evidence A1]

The median survival was 4.48 years (95% CI; range, 2.4–not estimable) for trimodality therapy versus 1.79 years (95% CI, 1.41–2.59) for surgery alone (P = .002), with a 5-year OS rate of 39% for trimodality therapy (95% CI, 21%–57%) versus 16% for surgery alone (95% CI, 5%–33%).

To further evaluate the impact of neoadjuvant chemoradiation therapy for early-stage disease, the FFCD 9901 study randomly assigned 195 patients with stage I or stage II esophageal cancer to receive surgery alone or neoadjuvant chemoradiation therapy (45 Gy in 25 fractions administered with two courses of 5-FU [800 mg/m2] and cisplatin [75 mg/m2]) followed by surgery.[25][Level of evidence A1]

Sources: 25 · Level of evidence A1

To further evaluate the impact of neoadjuvant chemoradiation therapy for early-stage disease, the FFCD 9901 study randomly assigned 195 patients with stage I or stage II esophageal cancer to receive surgery alone or neoadjuvant chemoradiation therapy (45 Gy in 25 fractions administered with two courses of 5-FU [800 mg/m2] and cisplatin [75 mg/m2]) followed by surgery.[25][Level of evidence A1]

At interim analysis, accrual to the study was stopped early because of futility.

With a median follow-up of 94 months, there was no significant improvement in 3-year OS rates with chemoradiation (48% vs. 53%; P = .94); there was a significantly higher postoperative mortality rate of 11.1% versus 3.4% (P = .049).

The NRG Oncology/RTOG-1010 trial (NCT01196390) evaluated the addition of trastuzumab to trimodality treatment (paclitaxel plus carboplatin and radiotherapy, followed by surgery) in patients with untreated HER2-overexpressing esophageal adenocarcinoma. This phase III trial entered 606 patients for HER2 assessment. A total of 203 patients with HER2-positive disease were randomly assigned to receive chemoradiation therapy plus trastuzumab (n = 102) or chemoradiation therapy alone (n = 101). The primary end point was DFS. The median duration of follow-up was 2.8 years.[27] In conclusion, this trial confirmed that trastuzumab does not have a role in the preoperative treatment of HER2-positive esophageal or gastroesophageal cancer, either with chemotherapy alone or with chemoradiation therapy.

Sources: NRG Oncology/RTOG-1010 · 27

The NRG Oncology/RTOG-1010 trial (NCT01196390) evaluated the addition of trastuzumab to trimodality treatment (paclitaxel plus carboplatin and radiotherapy, followed by surgery) in patients with untreated HER2-overexpressing esophageal adenocarcinoma. This phase III trial entered 606 patients for HER2 assessment. A total of 203 patients with HER2-positive disease were randomly assigned to receive chemoradiation therapy plus trastuzumab (n = 102) or chemoradiation therapy alone (n = 101). The primary end point was DFS. The median duration of follow-up was 2.8 years.[27] In conclusion, this trial confirmed that trastuzumab does not have a role in the preoperative treatment of HER2-positive esophageal or gastroesophageal cancer, either with chemotherapy alone or with chemoradiation therapy.

The median DFS was 19.6 months (95% CI, 13.5–26.2) for patients who received chemoradiation therapy plus trastuzumab and 14.2 months (10.5–23.0) for patients who received chemoradiation therapy alone (HR, 0.99; 95% CI, 0.71–1.39; log-rank P = .97).[27][Level of evidence B1]

Sources: 27 · Level of evidence B1

Grade 3 treatment-related adverse events occurred in 41 of 95 patients (43%) who received trastuzumab and 52 of 96 patients (54%) of patients who received chemoradiation therapy alone. Grade 4 treatment-related adverse events occurred in 20 patients (21%) who received trastuzumab and 21 patients (22%) who received chemoradiation therapy alone.

There were five treatment-related deaths in the trastuzumab group (bronchopleural fistula, esophageal anastomotic leak, lung infection, sudden death, and death not otherwise specified), and three deaths in the chemoradiation therapy group (two multiorgan failure and one sepsis).

Health professional · Treatment Option Overview for Esophageal Cancer

Preoperative Chemotherapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

The effects of preoperative chemotherapy are being evaluated in randomized trials. Several studies have demonstrated a survival benefit with preoperative chemotherapy compared with surgery alone.[28-30] However, one large randomized study failed to confirm a survival benefit with preoperative chemotherapy.[31] Compared with preoperative chemotherapy alone, preoperative chemoradiation therapy improves pathological response and may improve outcomes.[32]

Sources: 28 · 30 · 31 · 32

Evidence (preoperative chemotherapy):

An intergroup trial (NCT00525785) randomly assigned 440 patients with local and operable esophageal cancer of any cell type to three cycles of preoperative 5-FU and cisplatin followed by surgery and two additional cycles of chemotherapy versus surgery alone.[31][Level of evidence A1]

Sources: NCT00525785 · 31 · Level of evidence A1

An intergroup trial (NCT00525785) randomly assigned 440 patients with local and operable esophageal cancer of any cell type to three cycles of preoperative 5-FU and cisplatin followed by surgery and two additional cycles of chemotherapy versus surgery alone.[31][Level of evidence A1]

After a median follow-up of 55 months, there were no significant differences in median survival between the chemotherapy-plus-surgery group (14.9 months) and the surgery-alone group (16.1 months). The median 2-year survival rate was 35% in the chemotherapy-plus-surgery group and 37% in the surgery-alone group.

The addition of chemotherapy did not increase the morbidity associated with surgery.

The Medical Research Council Oesophageal Cancer Working Party randomly assigned 802 patients with resectable esophageal cancer, also of any cell type, to two cycles of preoperative 5-FU and cisplatin followed by surgery versus surgery alone.[28][Level of evidence A1]The interpretation of the results from the intergroup and preoperative chemotherapy trials is challenging because T or N staging was not reported, and prerandomization and radiation could be offered at the discretion of the treating oncologist.

Sources: 28 · Level of evidence A1

The Medical Research Council Oesophageal Cancer Working Party randomly assigned 802 patients with resectable esophageal cancer, also of any cell type, to two cycles of preoperative 5-FU and cisplatin followed by surgery versus surgery alone.[28][Level of evidence A1]The interpretation of the results from the intergroup and preoperative chemotherapy trials is challenging because T or N staging was not reported, and prerandomization and radiation could be offered at the discretion of the treating oncologist.

At a median follow-up of 37 months, median survival was significantly improved in the preoperative chemotherapy arm (16.8 months vs. 13.3 months with surgery alone; 95% CI), as was the 2-year OS rate (43% in the preoperative chemotherapy arm and 34% in the surgery-alone arm; 95% CI).

The Japanese Clinical Oncology Group randomly assigned 330 patients with clinical stage II or III, excluding T4, squamous cell carcinomas to receive either two cycles of preoperative cisplatin and 5-FU followed by surgery or surgery followed by postoperative chemotherapy of the same regimen. A planned interim analysis was conducted after patient accrual. Although the primary end point of PFS was not met, there was a significant benefit in OS among patients treated with preoperative chemotherapy (P = .01). As a result of these findings, the Data and Safety Monitoring Committee recommended early closure of the study.[29][Level of evidence A3]

Sources: 29 · Level of evidence A3

The Japanese Clinical Oncology Group randomly assigned 330 patients with clinical stage II or III, excluding T4, squamous cell carcinomas to receive either two cycles of preoperative cisplatin and 5-FU followed by surgery or surgery followed by postoperative chemotherapy of the same regimen. A planned interim analysis was conducted after patient accrual. Although the primary end point of PFS was not met, there was a significant benefit in OS among patients treated with preoperative chemotherapy (P = .01). As a result of these findings, the Data and Safety Monitoring Committee recommended early closure of the study.[29][Level of evidence A3]

With a median follow-up of 61 months, the 5-year OS rate was 55% among patients treated with preoperative chemotherapy, compared with 43% among patients treated with postoperative chemotherapy (P = .04). However, there was no significant difference between groups with respect to PFS (5-year PFS rate, 39% vs. 44%; P = .22).

Additionally, there were no significant differences between the two groups with respect to postoperative complications or treatment-related toxicities.

The Fédération Nationale des Centres de Lutte contre le Cancer and the FFCD randomly assigned 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction, or stomach to receive either perioperative chemotherapy and surgery (n = 113) or surgery alone (n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous (IV) cisplatin (100 mg/m2) on day 1 and continuous IV infusion of 5-FU (800 mg/m2) for 5 consecutive days (day 1–5) every 28 days, and three or four postoperative cycles of the same regimen.[30][Level of evidence A1]

Sources: 30 · Level of evidence A1

The Fédération Nationale des Centres de Lutte contre le Cancer and the FFCD randomly assigned 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction, or stomach to receive either perioperative chemotherapy and surgery (n = 113) or surgery alone (n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous (IV) cisplatin (100 mg/m2) on day 1 and continuous IV infusion of 5-FU (800 mg/m2) for 5 consecutive days (day 1–5) every 28 days, and three or four postoperative cycles of the same regimen.[30][Level of evidence A1]

Perioperative chemotherapy was associated with an improved 5-year OS rate (38% vs. 24%; HR, 0.69; P = .02).

Grade 3 and 4 toxicity occurred in 38% of patients treated with perioperative chemotherapy, but there was no increase in postoperative morbidity.

The Preoperative Chemotherapy or Radiochemotherapy in Esophago-gastric Adenocarcinoma Trial (POET) sought to evaluate the additional benefit of radiation therapy to preoperative chemotherapy. Patients were randomly assigned to receive either induction chemotherapy (15 weeks) followed by surgery or chemotherapy (12 weeks) followed by chemoradiation therapy (3 weeks) and surgery.[32][Level of evidence A1]

Sources: 32 · Level of evidence A1

The Preoperative Chemotherapy or Radiochemotherapy in Esophago-gastric Adenocarcinoma Trial (POET) sought to evaluate the additional benefit of radiation therapy to preoperative chemotherapy. Patients were randomly assigned to receive either induction chemotherapy (15 weeks) followed by surgery or chemotherapy (12 weeks) followed by chemoradiation therapy (3 weeks) and surgery.[32][Level of evidence A1]

The study was closed early because of poor accrual. In total, 126 patients were randomly assigned.

Preoperative radiation therapy yielded 3-year survival rates of 27% to 47% (log-rank P = .07). The postoperative mortality rate was nonsignificantly increased in the chemoradiation therapy group (10.2% vs. 3.8%; P = .26).

Health professional · Treatment Option Overview for Esophageal Cancer

Perioperative Chemotherapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

A trial that included patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus randomly assigned 250 patients to receive perioperative chemotherapy and surgery and 253 patients to receive surgery alone. Chemotherapy consisted of three preoperative and three postoperative cycles of IV epirubicin (50 mg/m2) and cisplatin (60 mg/m2) on day 1, and a continuous IV infusion of 5-FU (200 mg/m2 per day) for 21 days. The primary end point was OS.[33]

Sources: 33

A trial that included patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus randomly assigned 250 patients to receive perioperative chemotherapy and surgery and 253 patients to receive surgery alone. Chemotherapy consisted of three preoperative and three postoperative cycles of IV epirubicin (50 mg/m2) and cisplatin (60 mg/m2) on day 1, and a continuous IV infusion of 5-FU (200 mg/m2 per day) for 21 days. The primary end point was OS.[33]

After a median follow-up of 4 years, 149 patients in the perioperative chemotherapy group and 170 patients in the surgery-alone group had died.

Compared with the surgery-alone group, the perioperative chemotherapy group had a higher likelihood of OS (HRdeath, 0.75; 95% CI, 0.60–0.93; P = .009). The 5-year survival rate was 36.3% in the perioperative chemotherapy group (95% CI, 29.5%–43.0%) and 23% (95% CI, 16.6%–29.4%) in the surgery-alone group.[33][Level of evidence A1]

Sources: 33 · Level of evidence A1

The PFS rate was also improved in the perioperative chemotherapy group (HRprogression, 0.66; 95% CI, 0.53–0.81; P < .001) compared with the surgery-alone group.

The rate of postoperative complications was similar in the two groups; 46% in the perioperative chemotherapy group and 45% in the surgery-alone group. The number of deaths within 30 days after surgery was also similar between the two groups.

An open-label, randomized, phase II/III trial compared the efficacy and safety of the docetaxel-based triplet FLOT regimen with the combination of epirubicin and cisplatin plus either 5-FU given as a continuous infusion or capecitabine given orally. The trial included 716 patients with adenocarcinoma in clinical stage cT2 or higher, node-positive stage (cN+), or both, or resectable tumors with no evidence of distant metastases. Patients were randomly assigned to receive either: (1) ECF/ECX (three preoperative and three postoperative 3-week cycles of epirubicin [50 mg/m2] and cisplatin [60 mg/m2] on day 1 plus either 5-FU [200 mg/m2] given as a continuous infusion or capecitabine [1,250 mg/m2] orally on days 1 to 21), or (2) FLOT (four preoperative and four postoperative 2-week cycles of docetaxel [50 mg/m2], oxaliplatin [85 mg/m2], leucovorin [200 mg/m2], and 5-FU [2,600 mg/m2] as a 24-hour infusion on day 1). The primary end point of the trial was OS (superiority) in the intention-to-treat population.[34]

Sources: 34

An open-label, randomized, phase II/III trial compared the efficacy and safety of the docetaxel-based triplet FLOT regimen with the combination of epirubicin and cisplatin plus either 5-FU given as a continuous infusion or capecitabine given orally. The trial included 716 patients with adenocarcinoma in clinical stage cT2 or higher, node-positive stage (cN+), or both, or resectable tumors with no evidence of distant metastases. Patients were randomly assigned to receive either: (1) ECF/ECX (three preoperative and three postoperative 3-week cycles of epirubicin [50 mg/m2] and cisplatin [60 mg/m2] on day 1 plus either 5-FU [200 mg/m2] given as a continuous infusion or capecitabine [1,250 mg/m2] orally on days 1 to 21), or (2) FLOT (four preoperative and four postoperative 2-week cycles of docetaxel [50 mg/m2], oxaliplatin [85 mg/m2], leucovorin [200 mg/m2], and 5-FU [2,600 mg/m2] as a 24-hour infusion on day 1). The primary end point of the trial was OS (superiority) in the intention-to-treat population.[34]

OS was longer in the FLOT group than the ECF/ECX group (HR, 0.77; 95% CI, 0.63–0.94). The median OS was 50 months in the FLOT group (38.33–not reached) and 35 months in the ECF/ECX group (27.35–46.26).[34][Level of evidence A1]

Sources: 34 · Level of evidence A1

The number of patients with related serious adverse events (including those occurring during a hospital stay for surgery) was similar between the two groups: 96 patients (27%) in the ECF/ECX group and 97 patients (27%) in the FLOT group.

The number of deaths due to toxicity (two [<1%]) was similar in both groups. Hospitalization for toxicity occurred in 94 patients (26%) in the ECF/ECX group and 89 patients (25%) in the FLOT group.

The ESOPEC trial (NCT02509286) compared (1) perioperative FLOT (four 2-week cycles of chemotherapy before surgery and four 2-week cycles of chemotherapy after surgery) and surgery with (2) neoadjuvant chemoradiation therapy with the CROSS regimen (41.4 Gy of radiation therapy plus carboplatin and docetaxel) followed by surgery. The trial enrolled 438 patients with clinical (c)T1, cN+, cM0 or cT2–4a, any cN, cM0 resectable esophageal adenocarcinoma. Patients were assigned to the FLOT group (n = 221) or the CROSS group (n = 217). The primary end point was OS.[35]In the ESOPEC trial, patients randomly assigned to the CROSS arm did not receive 1 year of adjuvant nivolumab. In the CheckMate 577 trial, 1 year of adjuvant nivolumab improved DFS when compared with placebo in patients who had resected specimens that did not show pathological complete responses. However, OS data from CheckMate 577 have not been published.

Sources: ESOPEC · 35

The ESOPEC trial (NCT02509286) compared (1) perioperative FLOT (four 2-week cycles of chemotherapy before surgery and four 2-week cycles of chemotherapy after surgery) and surgery with (2) neoadjuvant chemoradiation therapy with the CROSS regimen (41.4 Gy of radiation therapy plus carboplatin and docetaxel) followed by surgery. The trial enrolled 438 patients with clinical (c)T1, cN+, cM0 or cT2–4a, any cN, cM0 resectable esophageal adenocarcinoma. Patients were assigned to the FLOT group (n = 221) or the CROSS group (n = 217). The primary end point was OS.[35]In the ESOPEC trial, patients randomly assigned to the CROSS arm did not receive 1 year of adjuvant nivolumab. In the CheckMate 577 trial, 1 year of adjuvant nivolumab improved DFS when compared with placebo in patients who had resected specimens that did not show pathological complete responses. However, OS data from CheckMate 577 have not been published.

With a median follow-up of 55 months, the 3-year OS rate was 57.4% (95% CI, 50.1%–64.0%) in the FLOT group and 50.7% (95% CI, 43.5%–57.5%) in the CROSS group (HRdeath, 0.70; 95% CI, 0.53–0.92; P = .01). The median OS was 66 months (95% CI, 36–not estimable) in the FLOT group and 37 months (95% CI, 28–43) in the CROSS group.[35][Level of evidence A1]

Sources: 35 · Level of evidence A1

The 3-year PFS rate was 51.6% (95% CI, 44.3%–58.4%) in the FLOT group and 35.0% (95% CI, 28.4%–41.7%) in the CROSS group (HRdisease progression or death, 0.66; 95% CI, 0.51–0.85).

Neoadjuvant treatment was given to 403 patients: 207 patients in the FLOT group and 196 patients in the CROSS group. In the FLOT group 193 patients (89%) received four full cycles of chemotherapy before surgery, and 118 patients (53%) received four full cycles of chemotherapy after surgery. In the CROSS group, 147 patients (68%) received five full cycles of chemotherapy.

Surgery was performed in 374 patients: 192 patients in the FLOT group and 179 patients in the CROSS group. R0 resection occurred in 182 of 193 patients (94.3%) in the FLOT group and in 172 of 181 patients (95.0%) in the CROSS group.

Pathological complete response after surgery, defined as a pathological stage of ypT0 ypN0 (no residual invasive cancer in the resected primary tumor and lymph nodes), was seen in 32 of 192 patients (16.7%) in the FLOT group and 18 of 179 patients (10.1%) in the CROSS group.

At 90 days after surgery, 3.1% of patients in the FLOT group and 5.6% of patients in the CROSS group had died.

The study noted grade 3 or higher adverse events that occurred in 5% or more of patients. In the FLOT group, those adverse effects included neutropenia (19.8%), diarrhea (6.8%), leukopenia (6.3%), and pneumonia (5.8%). In the CROSS group, those adverse effects included leukopenia (9.7%) and pneumonia (9.2%).

Health professional · Treatment Option Overview for Esophageal Cancer

Definitive Chemoradiation Therapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

For patients who are deemed either medically inoperable or have tumors that are unresectable, the efficacy of definitive chemoradiation has been established in numerous randomized controlled trials.[36,37] For patients with squamous cell carcinomas of the esophagus, definitive chemoradiation may offer equivalent outcomes, compared with preoperative chemoradiation followed by surgical resection.[38,39]

Sources: 36 · 37 · 38 · 39

Evidence (definitive chemoradiation):

A Radiation Therapy Oncology Group trial (RTOG-8501) randomly assigned patients to receive radiation therapy alone (64 Gy in 32 fractions) or chemoradiation (50 Gy in 25 fractions) with concurrent cisplatin (75 mg/m2) and continuous-infusion 5-FU (1,000 mg/m2 on days 1 to 4 in weeks 1 and 5 followed by two additional cycles of chemotherapy administered 3 weeks apart).[36][Level of evidence A1]

Sources: 36 · Level of evidence A1

A Radiation Therapy Oncology Group trial (RTOG-8501) randomly assigned patients to receive radiation therapy alone (64 Gy in 32 fractions) or chemoradiation (50 Gy in 25 fractions) with concurrent cisplatin (75 mg/m2) and continuous-infusion 5-FU (1,000 mg/m2 on days 1 to 4 in weeks 1 and 5 followed by two additional cycles of chemotherapy administered 3 weeks apart).[36][Level of evidence A1]

There was an improvement in the 5-year survival rate for the combined modality group (27% vs. 0%).

An 8-year follow-up of this trial demonstrated an OS rate of 22% for patients who received chemoradiation therapy.

Intergroup-0123 (RTOG-9405 [NCT00002631]) was conducted in an attempt to improve upon the results of RTOG-8501. Intergroup-0123 randomly assigned 236 patients with localized esophageal tumors to undergo chemoradiation with high-dose radiation therapy (64.8 Gy) and four monthly cycles of 5-FU and cisplatin versus conventional-dose radiation therapy (50.4 Gy) and the same chemotherapy schedule.[37][Level of evidence A1]

Sources: RTOG-9405 · 37 · Level of evidence A1

Intergroup-0123 (RTOG-9405 [NCT00002631]) was conducted in an attempt to improve upon the results of RTOG-8501. Intergroup-0123 randomly assigned 236 patients with localized esophageal tumors to undergo chemoradiation with high-dose radiation therapy (64.8 Gy) and four monthly cycles of 5-FU and cisplatin versus conventional-dose radiation therapy (50.4 Gy) and the same chemotherapy schedule.[37][Level of evidence A1]

Although originally designed to accrue 298 patients, this trial was closed in 1999 after a planned interim analysis showed that it was statistically unlikely that there would be any advantage to using high-dose radiation.

At a 2-year median follow-up, no statistically significant differences in median survival were observed between the high-dose and conventional-dose radiation therapy arms (13 months vs. 18 months), 2-year survival rates (31% vs. 40%), or local and regional failure rates (56% vs. 52%).

There was a higher treatment mortality rate in the higher-dose arm (9% vs. 2%). However, 7 of 11 deaths in the high-dose arm occurred in patients who had received 50.4 Gy or less.

An Eastern Cooperative Oncology Group trial (EST-1282) evaluated 135 patients.[40][Level of evidence A1]

Sources: 40 · Level of evidence A1

An Eastern Cooperative Oncology Group trial (EST-1282) evaluated 135 patients.[40][Level of evidence A1]

This trial showed that chemotherapy plus radiation therapy provided a better 2-year survival rate than did radiation therapy alone, similar to results from the intergroup trial.

The PRODIGE5/ACCORD17 trial (NCTE) compared the efficacy and safety of oxaliplatin, 5-FU, and leucovorin calcium (FOLFOX) versus 5-FU and cisplatin as the chemotherapy backbone among patients treated with definitive chemoradiation for localized esophageal cancer. In this multicenter, randomized, phase II and III trial, 267 patients were randomly assigned to receive either six cycles of FOLFOX (three cycles concomitant with radiation therapy), oxaliplatin (85 mg/m2), leucovorin (200 mg/m2), bolus 5-FU (400 mg/m2), and infusion 5-FU (1,600 mg/m2 over 46 hours) or four cycles of 5-FU (1,000 mg/m2 for 4 days) and cisplatin (75 mg/m2 on day 1). All patients received radiation therapy (50 Gy in 25 fractions).[41][Level of evidence B1]

Sources: PRODIGE5/ACCORD17 · 41 · Level of evidence B1

The PRODIGE5/ACCORD17 trial (NCTE) compared the efficacy and safety of oxaliplatin, 5-FU, and leucovorin calcium (FOLFOX) versus 5-FU and cisplatin as the chemotherapy backbone among patients treated with definitive chemoradiation for localized esophageal cancer. In this multicenter, randomized, phase II and III trial, 267 patients were randomly assigned to receive either six cycles of FOLFOX (three cycles concomitant with radiation therapy), oxaliplatin (85 mg/m2), leucovorin (200 mg/m2), bolus 5-FU (400 mg/m2), and infusion 5-FU (1,600 mg/m2 over 46 hours) or four cycles of 5-FU (1,000 mg/m2 for 4 days) and cisplatin (75 mg/m2 on day 1). All patients received radiation therapy (50 Gy in 25 fractions).[41][Level of evidence B1]

With a median follow-up of 25.3 months, there was no significant difference in PFS (9.7 months with FOLFOX vs. 9.4 months with 5-FU and cisplatin; P = .64).

There was one death caused by toxicity in the FOLFOX group versus six deaths in the 5-FU and cisplatin arm (P = .066).

There were no significant differences in grade 3 or 4 adverse events between treatment groups. Among toxicities of all grades, paresthesia, sensory neuropathy, and increases in aspartate transaminase and alanine transaminase were more common in the FOLFOX group; increases in serum creatinine, mucositis, and alopecia were more common in the 5-FU and cisplatin group.

A phase III German trial also compared induction chemotherapy (three courses of bolus 5-FU, leucovorin, etoposide, and cisplatin) followed by chemoradiation therapy (cisplatin, etoposide, and 40 Gy) followed by surgery (arm A), or the same induction chemotherapy followed by chemoradiation therapy (at least 65 Gy) without surgery (arm B) for patients with T3 or T4 squamous cell carcinoma of the esophagus. OS was the primary outcome.[38][Level of evidence A1]

Sources: 38 · Level of evidence A1

A phase III German trial also compared induction chemotherapy (three courses of bolus 5-FU, leucovorin, etoposide, and cisplatin) followed by chemoradiation therapy (cisplatin, etoposide, and 40 Gy) followed by surgery (arm A), or the same induction chemotherapy followed by chemoradiation therapy (at least 65 Gy) without surgery (arm B) for patients with T3 or T4 squamous cell carcinoma of the esophagus. OS was the primary outcome.[38][Level of evidence A1]

The analysis of 172 eligible randomly assigned patients showed that OS rates at 2 years were not statistically significantly different between the two treatment groups (arm A, 39.9%; 95% CI, 29.4%–50.4%; arm B, 35.4%; 95% CI, 25.2%–45.6%; log-rank test for equivalence with 0.15, P < .007).

The local 2-year PFS rate was higher in the surgery group (64.3%; 95% CI, 52.1%–76.5%) than in the chemoradiation therapy group (40.7%; 95% CI, 28.9%–52.5%; HR for arm B vs. arm A, 2.1; 95% CI, 1.3–3.5; P < .003).

The treatment-related mortality rate was higher in the surgery group (12.8%) than in the chemoradiation therapy group (3.5%) (P < .03).

FFCD 9102 (NCTE) randomly assigned 259 patients with T3N0–1M0 thoracic esophageal cancer to receive either two cycles of 5-FU and cisplatin (days 1–5 and 22–26) and either conventional radiation therapy (46 Gy in 4.5 weeks) or split course (15 Gy, days 1–5 and 22–26). Patients with response were then randomly assigned to receive either surgical resection (arm A) or continuation of chemoradiation (arm B: three cycles of 5-FU plus cisplatin and either conventional 20 Gy or split-course 15 Gy radiation therapy).[39][Level of evidence A1]

Sources: FFCD 9102 · 39 · Level of evidence A1

FFCD 9102 (NCTE) randomly assigned 259 patients with T3N0–1M0 thoracic esophageal cancer to receive either two cycles of 5-FU and cisplatin (days 1–5 and 22–26) and either conventional radiation therapy (46 Gy in 4.5 weeks) or split course (15 Gy, days 1–5 and 22–26). Patients with response were then randomly assigned to receive either surgical resection (arm A) or continuation of chemoradiation (arm B: three cycles of 5-FU plus cisplatin and either conventional 20 Gy or split-course 15 Gy radiation therapy).[39][Level of evidence A1]

Of the 259 randomly assigned patients, 230 (89%) had squamous cell carcinoma, and 29 patients (11%) had adenocarcinomas.

The 2-year OS rate was 34% in patients randomly assigned to receive surgery versus 40% in patients randomly assigned to receive definitive chemoradiation (HR, 0.90; P = .44). Median survival was 17.7 months for surgery and 19.3 months for definitive chemoradiation.

The 3-month mortality rate was 9.3% in the surgery arm, compared with 0.8% in the chemoradiation arm (P = .002).

Health professional · Treatment Option Overview for Esophageal Cancer

Adjuvant Therapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Evidence (adjuvant therapy):

A global, randomized, double-blind, placebo-controlled, phase III trial evaluated a checkpoint inhibitor as adjuvant therapy in 794 patients with esophageal or gastroesophageal junction cancer. Adults with a performance status of 0 or 1 and R0 stage II or III disease who had received neoadjuvant chemoradiation therapy and had residual pathological disease were included. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (240 mg every 2 weeks for 16 weeks) followed by nivolumab (480 mg every 4 weeks) (532 patients) or matching placebo (262 patients). Patients were enrolled regardless of programmed death-ligand 1 (PD-L1) expression. The maximum duration of the trial intervention period was 1 year. The primary end point was DFS. The median follow-up was 24.4 months.[42][Level of evidence B1]

Sources: 42 · Level of evidence B1

A global, randomized, double-blind, placebo-controlled, phase III trial evaluated a checkpoint inhibitor as adjuvant therapy in 794 patients with esophageal or gastroesophageal junction cancer. Adults with a performance status of 0 or 1 and R0 stage II or III disease who had received neoadjuvant chemoradiation therapy and had residual pathological disease were included. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (240 mg every 2 weeks for 16 weeks) followed by nivolumab (480 mg every 4 weeks) (532 patients) or matching placebo (262 patients). Patients were enrolled regardless of programmed death-ligand 1 (PD-L1) expression. The maximum duration of the trial intervention period was 1 year. The primary end point was DFS. The median follow-up was 24.4 months.[42][Level of evidence B1]

The median DFS was 22.4 months (95% CI, 16.6–34.0) among patients who received nivolumab, compared with 11.0 months (95% CI, 8.3–14.3) among patients who received placebo. The HRdisease recurrence or death was 0.69 (96.4% CI, 0.56–0.86; P < .001).

Median DFS was evaluated across a prespecified subgroup according to histological type. Among patients with adenocarcinoma, the median DFS was 19.4 months in the 376 patients who received nivolumab (95% CI, 15.9–29.4), compared with 11.1 months in the 187 patients who received the placebo (95% CI, 8.3–16.8); the HRdisease recurrence or death was 0.75 (95% CI, 0.59–0.96). Among patients with squamous cell carcinoma, the median DFS was 29.7 months (95% CI, 14.4 to not estimable) in the 155 patients who received nivolumab, compared with 11 months (95% CI, 7.6–17.8) in the 75 patients who received the placebo; the HRdisease recurrence or death was 0.61 (95% CI, 0.42–0.88).

HRs for disease recurrence or death were remarkably close between the 570 patients whose tumors expressed less than 1% of PD-L1 (HR, 0.73; 95% CI, 0.57–0.92) and the 129 patients whose tumors expressed 1% or more of PD-L1 (HR, 0.75; 95% CI, 0.45–1.24).

Grade 3 or 4 adverse events of any cause occurred in 183 of 532 patients (34%) in the nivolumab group and 84 of 260 patients (32%) in the placebo group, and serious adverse events of any grade occurred in 30% of the patients in each group (nivolumab: 158 of 532; placebo: 78 of 260). Adverse events that were considered by the investigators to be related to the trial regimen were more common with nivolumab than with placebo, including grade 3 or 4 events (nivolumab: 71 of 532 patients [13%]; placebo: 15 of 260 patients [6%]) and events leading to discontinuation of therapy (nivolumab: 48 of 532 patients [9%]; placebo: 8 of 260 patients [3%]).

OS data have not been reported for this study.

Given the positive results for the use of nivolumab after chemoradiation therapy and surgery in patients with esophageal cancer, an ongoing study will determine whether the adjuvant use of checkpoint inhibitor therapy improves outcomes in patients undergoing definitive chemoradiation therapy without surgery (KEYNOTE-975 [NCT04210115]).

Sources: KEYNOTE-975

Health professional · Treatment Option Overview for Esophageal Cancer

Immunotherapy and Chemoimmunotherapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Esophageal Cancer / Immunotherapy and Chemoimmunotherapy

Immunotherapy and chemoimmunotherapy for patients with squamous cell carcinoma

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Phase III randomized trials have compared chemotherapy with chemoimmunotherapy as first-line treatment for patients with advanced squamous cell carcinoma.[43-45]

Sources: 43 · 45

Evidence (immunotherapy and chemoimmunotherapy for patients with squamous cell carcinoma):

In the CheckMate 648 trial (NCT03143153), 970 adults with previously untreated, unresectable advanced, recurrent, or metastatic squamous cell carcinoma were enrolled, regardless of tumor cell PD-L1 expression. Patients were randomly assigned to receive either nivolumab (240 mg every 2 weeks) plus chemotherapy with 5-FU and cisplatin (every 4 weeks), nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks), or chemotherapy alone. Primary end points for all groups were OS and PFS per blinded independent central review in patients with tumor cell PD-L1 expression of 1% or more (observed in 49% of patients). Further analyses included all patients regardless of PD-L1 status.[43]

Sources: CheckMate 648 · 43

In the CheckMate 648 trial (NCT03143153), 970 adults with previously untreated, unresectable advanced, recurrent, or metastatic squamous cell carcinoma were enrolled, regardless of tumor cell PD-L1 expression. Patients were randomly assigned to receive either nivolumab (240 mg every 2 weeks) plus chemotherapy with 5-FU and cisplatin (every 4 weeks), nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks), or chemotherapy alone. Primary end points for all groups were OS and PFS per blinded independent central review in patients with tumor cell PD-L1 expression of 1% or more (observed in 49% of patients). Further analyses included all patients regardless of PD-L1 status.[43]

In patients with PD-L1-positive disease, the median OS was 15.4 months for patients who received nivolumab plus chemotherapy (95% CI, 11.9–19.5; n = 158), 13.7 months for patients who received nivolumab plus ipilimumab (95% CI, 11.2–17.0; n = 158), and 9.1 months for patients who received chemotherapy alone (95% CI, 7.7–10.0; n = 157). The corresponding HR (vs. chemotherapy) was 0.54 (99.5% CI, 0.37–0.8; P < .0001) for patients who received nivolumab plus chemotherapy and 0.64 (98.6% CI, 0.46–0.9; P < .001) for patients who received nivolumab plus ipilimumab.[43][Level of evidence A1]

Sources: 43 · Level of evidence A1

A statistically significant improvement in median OS, compared with chemotherapy, was also observed in all randomized patients, irrespective of PD-L1 status. Median OS was 13.2 months for patients who received nivolumab plus chemotherapy (95% CI, 11.1–15.7; n = 321), 12.8 months for patients who received nivolumab plus ipilimumab (95% CI, 11.3–15.5; n = 325), and 10.7 months for patients who received chemotherapy alone (95% CI, 9.4–11.9; n = 324). The corresponding HR (vs. chemotherapy) was 0.74 (99.1% CI, 0.58–0.96; P = .0021) for patients who received nivolumab plus chemotherapy and 0.78 (98.2% CI, 0.62–0.98; P = .011) for patients who received nivolumab plus ipilimumab.[43][Level of evidence A1]

Sources: 43 · Level of evidence A1

However, among patients whose tumors expressed less than 1% of PD-L1, OS was not significantly changed by the addition of nivolumab to chemotherapy (n = 329; median OS, 12.2 months with chemotherapy and 12 months with nivolumab plus chemotherapy) or by the combination of nivolumab with ipilimumab (n = 330; median OS, 12.2 months with chemotherapy and 12 months with nivolumab plus ipilimumab).

Grade 3 or higher adverse events occurred in 147 patients (47%) who received nivolumab plus chemotherapy, 102 patients (32%) who received nivolumab plus ipilimumab, and 108 patients (36%) who received chemotherapy alone. No new safety signals were observed.

The results of ESCORT-1st (NCT03691090), a randomized, double-blind, multicenter, placebo-controlled trial conducted in China, corroborated the positive impact of checkpoint inhibitors combined with first-line chemotherapy on patient survival. In this trial, 596 patients with previously untreated locally advanced or metastatic esophageal squamous cell cancer were randomly assigned (1:1) to receive either the humanized anti-PD-1 monoclonal antibody camrelizumab (200 mg; n = 298) or placebo (n = 298). Patients in both groups also received up to 6 cycles of paclitaxel (175 mg/m2) and cisplatin (75 mg/m2). All drugs were given IV every 3 weeks. Co-primary end points were OS and independent review committee (IRC)-assessed PFS.[44]Camrelizumab is only approved for use in China.

Sources: ESCORT-1st · 44

The results of ESCORT-1st (NCT03691090), a randomized, double-blind, multicenter, placebo-controlled trial conducted in China, corroborated the positive impact of checkpoint inhibitors combined with first-line chemotherapy on patient survival. In this trial, 596 patients with previously untreated locally advanced or metastatic esophageal squamous cell cancer were randomly assigned (1:1) to receive either the humanized anti-PD-1 monoclonal antibody camrelizumab (200 mg; n = 298) or placebo (n = 298). Patients in both groups also received up to 6 cycles of paclitaxel (175 mg/m2) and cisplatin (75 mg/m2). All drugs were given IV every 3 weeks. Co-primary end points were OS and independent review committee (IRC)-assessed PFS.[44]Camrelizumab is only approved for use in China.

With a median follow-up of 10.8 months, patients who received camrelizumab plus chemotherapy had significantly improved OS compared with patients who received placebo plus chemotherapy (median OS, 15.3 months [95% CI, 12.8–17.3] vs. 12.0 months [11.0–13.3]; HR, 0.70; 95% CI, 0.56–0.88; one-sided P = .0010).

Grade 3 or higher treatment-related adverse events occurred in 189 patients (63.4%) in the camrelizumab group and 201 patients (67.7%) in the placebo group. Treatment-related deaths occurred in 9 patients (3.0%) in the camrelizumab group and 11 patients (3.7%) in the placebo group.

In KEYNOTE-590 (NCT03189719), a double-blind, placebo-controlled, randomized, phase III trial, 1,020 patients with previously untreated, locally advanced, unresectable, or metastatic esophageal cancer or Siewert type 1 gastroesophageal junction cancer (regardless of PD-L1 status) were screened.[45] A total of 749 patients were randomly assigned (1:1) to receive either pembrolizumab (200 mg) or placebo plus chemotherapy (5-FU at 800 mg/m2 on days 1–5 and cisplatin 80 mg/m2 on day 1 [for up to 6 cycles]). Treatment was repeated once every 3 weeks for up to 35 cycles. The primary end points were: (1) OS in patients with esophageal squamous cell carcinoma and a PD-L1 combined positive score (CPS) of 10 or more, and (2) OS and PFS in patients with esophageal squamous cell carcinoma, patients with a PD-L1 CPS of 10 or more irrespective of the histology, and all randomized patients. A total of 548 enrolled patients (73%) had squamous cell histology, 286 of whom (52%) had a CPS of 10 or more.Notably, in an exploratory analysis in patients with a PD-L1 CPS of less than 10, median OS was 10.5 months in the pembrolizumab and chemotherapy group versus 10.6 months in the placebo and chemotherapy group (HR, 0.86; 95% CI, 0.68–1.10).

Sources: KEYNOTE-590 · 45

In KEYNOTE-590 (NCT03189719), a double-blind, placebo-controlled, randomized, phase III trial, 1,020 patients with previously untreated, locally advanced, unresectable, or metastatic esophageal cancer or Siewert type 1 gastroesophageal junction cancer (regardless of PD-L1 status) were screened.[45] A total of 749 patients were randomly assigned (1:1) to receive either pembrolizumab (200 mg) or placebo plus chemotherapy (5-FU at 800 mg/m2 on days 1–5 and cisplatin 80 mg/m2 on day 1 [for up to 6 cycles]). Treatment was repeated once every 3 weeks for up to 35 cycles. The primary end points were: (1) OS in patients with esophageal squamous cell carcinoma and a PD-L1 combined positive score (CPS) of 10 or more, and (2) OS and PFS in patients with esophageal squamous cell carcinoma, patients with a PD-L1 CPS of 10 or more irrespective of the histology, and all randomized patients. A total of 548 enrolled patients (73%) had squamous cell histology, 286 of whom (52%) had a CPS of 10 or more.Notably, in an exploratory analysis in patients with a PD-L1 CPS of less than 10, median OS was 10.5 months in the pembrolizumab and chemotherapy group versus 10.6 months in the placebo and chemotherapy group (HR, 0.86; 95% CI, 0.68–1.10).

At the first interim analysis (after a median follow-up of 22.6 months), patients who received pembrolizumab plus chemotherapy had superior OS compared with patients who received placebo plus chemotherapy for each of the following subgroups:[45][Level of evidence A1]

Sources: 45 · Level of evidence A1

In KEYNOTE-590 (NCT03189719), a double-blind, placebo-controlled, randomized, phase III trial, 1,020 patients with previously untreated, locally advanced, unresectable, or metastatic esophageal cancer or Siewert type 1 gastroesophageal junction cancer (regardless of PD-L1 status) were screened.[45] A total of 749 patients were randomly assigned (1:1) to receive either pembrolizumab (200 mg) or placebo plus chemotherapy (5-FU at 800 mg/m2 on days 1–5 and cisplatin 80 mg/m2 on day 1 [for up to 6 cycles]). Treatment was repeated once every 3 weeks for up to 35 cycles. The primary end points were: (1) OS in patients with esophageal squamous cell carcinoma and a PD-L1 combined positive score (CPS) of 10 or more, and (2) OS and PFS in patients with esophageal squamous cell carcinoma, patients with a PD-L1 CPS of 10 or more irrespective of the histology, and all randomized patients. A total of 548 enrolled patients (73%) had squamous cell histology, 286 of whom (52%) had a CPS of 10 or more.Notably, in an exploratory analysis in patients with a PD-L1 CPS of less than 10, median OS was 10.5 months in the pembrolizumab and chemotherapy group versus 10.6 months in the placebo and chemotherapy group (HR, 0.86; 95% CI, 0.68–1.10). › At the first interim analysis (after a median follow-up of 22.6 months), patients who received pembrolizumab plus chemotherapy had superior OS compared with patients who received placebo plus chemotherapy for each of the following subgroups:[45][Level of evidence A1]

Patients with esophageal squamous cell carcinoma and a PD-L1 CPS of 10 or more (median OS, 13.9 months vs. 8.8 months; HR, 0.57; 95% CI, 0.43–0.75; P < .0001).

Patients with esophageal squamous cell carcinoma (OS, 12.6 months vs. 9.8 months; HR, 0.72; 95% CI, 0.60–0.88; P = .0006).

Patients with a PD-L1 CPS of 10 or more (OS, 13.5 months vs. 9.4 months; HR, 0.62; 95% CI, 0.49–0.78; P < .0001).

All randomized patients (OS, 12.4 months vs. 9.8 months; HR, 0.73; 95% CI, 0.62–0.86; P < .0001).

In KEYNOTE-590 (NCT03189719), a double-blind, placebo-controlled, randomized, phase III trial, 1,020 patients with previously untreated, locally advanced, unresectable, or metastatic esophageal cancer or Siewert type 1 gastroesophageal junction cancer (regardless of PD-L1 status) were screened.[45] A total of 749 patients were randomly assigned (1:1) to receive either pembrolizumab (200 mg) or placebo plus chemotherapy (5-FU at 800 mg/m2 on days 1–5 and cisplatin 80 mg/m2 on day 1 [for up to 6 cycles]). Treatment was repeated once every 3 weeks for up to 35 cycles. The primary end points were: (1) OS in patients with esophageal squamous cell carcinoma and a PD-L1 combined positive score (CPS) of 10 or more, and (2) OS and PFS in patients with esophageal squamous cell carcinoma, patients with a PD-L1 CPS of 10 or more irrespective of the histology, and all randomized patients. A total of 548 enrolled patients (73%) had squamous cell histology, 286 of whom (52%) had a CPS of 10 or more.Notably, in an exploratory analysis in patients with a PD-L1 CPS of less than 10, median OS was 10.5 months in the pembrolizumab and chemotherapy group versus 10.6 months in the placebo and chemotherapy group (HR, 0.86; 95% CI, 0.68–1.10).

The 24-month OS rate in each of the above subgroups was double in the pembrolizumab and chemotherapy group compared with the placebo and chemotherapy group (approximately 30% vs. 15%).

Grade 3 or higher treatment-related adverse events occurred in 266 patients (72%) in the pembrolizumab group and 250 patients (68%) in the placebo group.

Health professional · Treatment Option Overview for Esophageal Cancer / Immunotherapy and Chemoimmunotherapy

Immunotherapy and chemoimmunotherapy for patients with adenocarcinoma

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

In 2021, the U.S. Food and Drug Administration approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma after the publication of the results of the CheckMate-649 trial.[46]

Sources: 46

Evidence (immunotherapy and chemoimmunotherapy for patients with adenocarcinoma):

In a randomized, open-label, international, phase III study (CheckMate-649 [NCT02872116]), 1,581 patients (including 955 with a PD-L1 CPS ≥5) with HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinomas were randomly assigned (1:1:1) (1:1 after enrollment in the nivolumab-plus-ipilimumab group was closed). A total of 789 patients (473 with a PD-L1 CPS ≥5) were assigned to receive nivolumab and chemotherapy (nivolumab 360 mg with capecitabine and oxaliplatin every 3 weeks, or nivolumab 240 mg with FOLFOX every 2 weeks). A total of 792 patients (482 with a PD-L1 CPS ≥5) were assigned to receive chemotherapy alone (capecitabine and oxaliplatin every 3 weeks or FOLFOX every 2 weeks). Disease site of origin was as follows: 1,100 patients (70%) had gastric adenocarcinoma, 260 patients (17%) had gastroesophageal junction carcinoma, and 211 patients (13%) had esophageal adenocarcinoma.[46]

Sources: CheckMate-649 · 46

In a randomized, open-label, international, phase III study (CheckMate-649 [NCT02872116]), 1,581 patients (including 955 with a PD-L1 CPS ≥5) with HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinomas were randomly assigned (1:1:1) (1:1 after enrollment in the nivolumab-plus-ipilimumab group was closed). A total of 789 patients (473 with a PD-L1 CPS ≥5) were assigned to receive nivolumab and chemotherapy (nivolumab 360 mg with capecitabine and oxaliplatin every 3 weeks, or nivolumab 240 mg with FOLFOX every 2 weeks). A total of 792 patients (482 with a PD-L1 CPS ≥5) were assigned to receive chemotherapy alone (capecitabine and oxaliplatin every 3 weeks or FOLFOX every 2 weeks). Disease site of origin was as follows: 1,100 patients (70%) had gastric adenocarcinoma, 260 patients (17%) had gastroesophageal junction carcinoma, and 211 patients (13%) had esophageal adenocarcinoma.[46]

The median follow-up for OS was 13.1 months (interquartile range [IQR], 6.7–19.1) for the nivolumab-plus-chemotherapy group and 11.1 months (IQR, 5.8–16.1) for the chemotherapy-alone group. Nivolumab plus chemotherapy resulted in improvements in OS (14.4 vs. 11.1 months; HR, 0.71; 98.4% CI, 0.59–0.86; P < .0001) and PFS (HR, 0.68; 98% CI, 0.56–0.81; P < .0001) compared with chemotherapy alone in patients with a PD-L1 CPS of 5 or more (minimum follow-up, 12.1 months).[46][Level of evidence A1]

Sources: 46 · Level of evidence A1

The unstratified HROS for patients with a PD-L1 CPS of less than 1 who received nivolumab plus chemotherapy versus chemotherapy alone was 0.92 (95% CI, 0.70–1.23). For patients with a PD-L1 CPS of less than 5, the HR was 0.94 (0.78–1.13).

Grades 3 and 4 adverse events occurred in 462 patients (59%) in the nivolumab group and in 341 patients (44%) in the chemotherapy-alone group.

The 3-year efficacy and safety results (minimum follow-up, 36.2 months for patients with a PD-L1 CPS ≥5) reported that the median OS and PFS were substantially unchanged. The OS rate was 21% in the nivolumab-plus-chemotherapy group and 10% in the chemotherapy-alone group. The PFS rate was 13% in the nivolumab-plus-chemotherapy group and 8% in the chemotherapy-alone group.[47]

Sources: 47

In KEYNOTE-590 (NCT03189719), patients with esophageal cancer or gastroesophageal junction cancer received either pembrolizumab or placebo plus chemotherapy. A total of 221 patients (27%) had adenocarcinoma histology. For study details, see the Immunotherapy and chemoimmunotherapy for patients with squamous cell carcinoma section.[45]

Sources: KEYNOTE-590 · Immunotherapy and chemoimmunotherapy for patients with squamous cell carcinoma · 45

The role of nivolumab in combination with chemotherapy was also assessed in ATTRACTION-4 (NCT02746796), a randomized, multicenter, double-blind, placebo-controlled, phase III trial. The study enrolled patients with previously untreated (except for neoadjuvant or adjuvant chemotherapy completed ≥180 days before recurrence), HER2-negative, unresectable, advanced or recurrent gastric or gastroesophageal junction cancer, regardless of PD-L1 expression. Only 9% of enrolled patients had gastroesophageal junction cancer. Patients were randomly assigned (1:1) to receive chemotherapy every 3 weeks (oxaliplatin 130 mg/m² IV on day 1 plus either oral S-1 40 mg/m² or oral capecitabine 1,000 mg/m², twice daily on days 1–14), in addition to either 360 mg nivolumab IV or placebo. The trial was conducted in Japan, South Korea, and Taiwan, and assigned 724 patients to treatment: 362 patients to the nivolumab-plus-chemotherapy group and 362 to the placebo-plus-chemotherapy group. The primary end points were centrally assessed PFS and OS in the intention-to-treat population.[48]

Sources: ATTRACTION-4 · 48

The role of nivolumab in combination with chemotherapy was also assessed in ATTRACTION-4 (NCT02746796), a randomized, multicenter, double-blind, placebo-controlled, phase III trial. The study enrolled patients with previously untreated (except for neoadjuvant or adjuvant chemotherapy completed ≥180 days before recurrence), HER2-negative, unresectable, advanced or recurrent gastric or gastroesophageal junction cancer, regardless of PD-L1 expression. Only 9% of enrolled patients had gastroesophageal junction cancer. Patients were randomly assigned (1:1) to receive chemotherapy every 3 weeks (oxaliplatin 130 mg/m² IV on day 1 plus either oral S-1 40 mg/m² or oral capecitabine 1,000 mg/m², twice daily on days 1–14), in addition to either 360 mg nivolumab IV or placebo. The trial was conducted in Japan, South Korea, and Taiwan, and assigned 724 patients to treatment: 362 patients to the nivolumab-plus-chemotherapy group and 362 to the placebo-plus-chemotherapy group. The primary end points were centrally assessed PFS and OS in the intention-to-treat population.[48]

At the time of data cutoff, with a median follow-up of 11.6 months, the median PFS was 10.45 months (95% CI, 8.44–14.75) in the nivolumab-plus-chemotherapy group and 8.34 months (6.97–9.40) in the placebo-plus-chemotherapy group (HR, 0.68; 98.51% CI, 0.51–0.90; P = .0007).[48][Level of evidence B1]

Sources: 48 · Level of evidence B1

At the time of data cutoff, with a median follow-up of 26.6 months, the median OS at the final analysis was 17.45 months (95% CI, 15.67–20.83) in the nivolumab-plus-chemotherapy group and 17.15 months (15.18–19.65) in the placebo-plus-chemotherapy group (HR, 0.90; 95% CI, 0.75–1.08; P = .26).[48][Level of evidence A1]

Sources: 48 · Level of evidence A1

The most common treatment-related grade 3 or 4 adverse events were decreased neutrophil count (observed in 20% of patients in the nivolumab-plus-chemotherapy group vs. 16% of patients in the placebo-plus-chemotherapy group) and decreased platelet count (observed in 9% of patients in both groups).

Six treatment-related deaths occurred: three in the nivolumab-plus-chemotherapy group (one each of febrile neutropenia, hepatic failure, and sudden death) and three in the placebo-plus-chemotherapy group (one each of sepsis, hemolytic anemia, and interstitial lung disease).

Tumor PD-L1 expression was at least 1% in 16% of patients randomized to the nivolumab arm and 15% of patients randomized to the placebo arm.

When the 3-year follow-up data were reported, the median PFS and OS remained substantially unchanged. The PFS rate was 27.4% in the nivolumab-plus-chemotherapy group and 12.3% in the placebo-plus-chemotherapy group. The OS rate was 23.9% in the nivolumab-plus-chemotherapy group and 19.4% in the placebo-plus-chemotherapy group. No new safety signals or major late-onset treatment-related adverse events were observed in patients who received nivolumab plus chemotherapy.[49]

Sources: 49

The multicenter, randomized, placebo-controlled, double-blind, phase III KEYNOTE-585 trial (NCT03221426) evaluated the role of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition in patients with locally advanced, resectable gastric or gastroesophageal adenocarcinoma. Patients were randomly assigned (1:1) to receive treatment in the following order: A small cohort (n = 203) was instead randomly assigned (1:1) to receive treatment in the following order: The primary end points were centrally reviewed pathological complete response, investigator-reviewed event-free survival (EFS), OS in the intention-to-treat population, and safety in all patients who received at least one dose of treatment.[50] In this trial, meeting the primary end point of pathological complete response did not translate to improvement in relevant primary clinical objectives like OS and EFS. Furthermore, no differential activity was demonstrated in the experimental group based on PD-L1 expression, according to CPS (cutoff, 1%). This was the first published trial evaluating the role of checkpoint inhibitors when given perioperatively to patients with operable gastric or gastroesophageal cancer. Therefore, pending EFS and OS results from studies that used durvalumab or toripalimab are imperative for understanding.

Sources: KEYNOTE-585 · 50

The multicenter, randomized, placebo-controlled, double-blind, phase III KEYNOTE-585 trial (NCT03221426) evaluated the role of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition in patients with locally advanced, resectable gastric or gastroesophageal adenocarcinoma. Patients were randomly assigned (1:1) to receive treatment in the following order: A small cohort (n = 203) was instead randomly assigned (1:1) to receive treatment in the following order: The primary end points were centrally reviewed pathological complete response, investigator-reviewed event-free survival (EFS), OS in the intention-to-treat population, and safety in all patients who received at least one dose of treatment.[50] In this trial, meeting the primary end point of pathological complete response did not translate to improvement in relevant primary clinical objectives like OS and EFS. Furthermore, no differential activity was demonstrated in the experimental group based on PD-L1 expression, according to CPS (cutoff, 1%). This was the first published trial evaluating the role of checkpoint inhibitors when given perioperatively to patients with operable gastric or gastroesophageal cancer. Therefore, pending EFS and OS results from studies that used durvalumab or toripalimab are imperative for understanding.

Neoadjuvant pembrolizumab (200 mg IV) or placebo plus cisplatin-based doublet chemotherapy (main cohort, N = 804) every 3 weeks for three cycles.

Surgery, adjuvant pembrolizumab or placebo, and chemotherapy for three cycles.

Adjuvant pembrolizumab or placebo for 11 cycles.

Neoadjuvant pembrolizumab or placebo plus FLOT-based chemotherapy (FLOT cohort) every 2 weeks for four cycles.

Surgery, adjuvant pembrolizumab or placebo, plus FLOT for four cycles.

Adjuvant pembrolizumab or placebo for 11 cycles.

In the main cohort of 804 patients, after a median follow-up of 47.7 months, 52 of 402 patients (12.9%; 95% CI, 9.8%–16.6%) who received pembrolizumab had pathological complete responses. In contrast, only 8 of 402 patients (2.0%; 95% CI, 0.9%–3.9%) who received placebo had pathological complete responses (difference 10.9%; 95% CI, 7.5–14.8; P < .00001).[50][Level of evidence B3]

Sources: 50 · Level of evidence B3

The median EFS was longer when patients received pembrolizumab (44.4 months, 95% CI, 33.0–not reached) when compared with placebo (25.3 months, 95% CI, 20.6–33.9) (HR, 0.81; 95% CI, 0.67–0.99; P = .0198). These values did not meet the threshold for statistical significance (P = .0178).

The median OS was 60.7 months (95% CI, 51.5–not reached) in the pembrolizumab group and 58.0 months (41.5–not reached) in the placebo group (HR, 0.90; 95% CI, 0.73–1.12; P = .174).

Grade 3 or higher adverse events of any cause occurred in 312 of 399 patients (78%) in the pembrolizumab group and 297 of 400 patients (74%) in the placebo group. The most common adverse events in patients who received pembrolizumab versus placebo were nausea (60% vs. 62%), anemia (42% vs. 40%), and decreased appetite (41% vs. 43%).

Health professional · Treatment Option Overview for Esophageal Cancer / Immunotherapy and Chemoimmunotherapy

Immunotherapy for patients who relapse after one prior line of standard therapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Pembrolizumab or nivolumab can be given to patients with esophageal cancer who were previously treated with a chemotherapy regimen that did not include an immune checkpoint inhibitor. Pembrolizumab is appropriate for patients with squamous or adenocarcinoma histology and a CPS of 10 or more. Nivolumab can be given to patients with squamous or adenosquamous histology, regardless of PD-L1 expression.

Evidence (immunotherapy for patients who relapse after one prior line of standard therapy):

The open-label phase II KEYNOTE-181 study (NCT02564263) included 628 patients with advanced or metastatic squamous cell carcinoma (n = 401) or adenocarcinoma (n = 227) of the esophagus that progressed after one prior therapy. Patients were randomly assigned (1:1) to receive either pembrolizumab (200 mg every 3 weeks for up to 2 years) or chemotherapy (investigator’s choice of paclitaxel, docetaxel, or irinotecan). Primary end points were OS in patients with a PD-L1 CPS of 10 or more, OS in patients with squamous cell carcinoma, and OS in all patients (one-sided alpha, 0.9%, 0.8%, and 0.8%, respectively).[51]

Sources: KEYNOTE-181 · 51

The open-label phase II KEYNOTE-181 study (NCT02564263) included 628 patients with advanced or metastatic squamous cell carcinoma (n = 401) or adenocarcinoma (n = 227) of the esophagus that progressed after one prior therapy. Patients were randomly assigned (1:1) to receive either pembrolizumab (200 mg every 3 weeks for up to 2 years) or chemotherapy (investigator’s choice of paclitaxel, docetaxel, or irinotecan). Primary end points were OS in patients with a PD-L1 CPS of 10 or more, OS in patients with squamous cell carcinoma, and OS in all patients (one-sided alpha, 0.9%, 0.8%, and 0.8%, respectively).[51]

At final analysis, conducted 16 months after the last patient was randomly assigned, OS was prolonged in patients with a CPS of 10 or more who received pembrolizumab versus chemotherapy (median OS, 9.3 vs. 6.7 months; HR, 0.69; 95% CI, 0.52–0.93; P = .0074).[51][Level of evidence A1]

Sources: 51 · Level of evidence A1

Among patients with squamous cell carcinoma, the median OS was 8.2 months for patients who received pembrolizumab and 7.1 months for patients who received chemotherapy (HR, 0.78; 95% CI, 0.63–0.96; P = .0095). Among all patients, the median OS was 7.1 months for patients who received pembrolizumab and 7.1 months for patients who received chemotherapy (HR, 0.89; 95% CI, 0.75–1.05; P = .0560).

Grade 3 to 5 treatment-related adverse events occurred in 18.2% of patients who received pembrolizumab and 40.9% of patients who received chemotherapy.

Patients in this study had not received prior immunotherapy.

The ATTRACTION-3 study (NCT02569242), a multicenter, randomized, open-label, phase III trial, included 419 patients with squamous or adenosquamous esophageal cancer refractory or intolerant to one previous fluoropyrimidine-based and platinum-based chemotherapy. Patients were randomly assigned (1:1) to receive either nivolumab (240 mg every 2 weeks) (n = 210) or investigator's choice of chemotherapy (weekly paclitaxel or docetaxel every 3 weeks) (n = 209). The primary end point was OS.[52]

Sources: ATTRACTION-3 · 52

The ATTRACTION-3 study (NCT02569242), a multicenter, randomized, open-label, phase III trial, included 419 patients with squamous or adenosquamous esophageal cancer refractory or intolerant to one previous fluoropyrimidine-based and platinum-based chemotherapy. Patients were randomly assigned (1:1) to receive either nivolumab (240 mg every 2 weeks) (n = 210) or investigator's choice of chemotherapy (weekly paclitaxel or docetaxel every 3 weeks) (n = 209). The primary end point was OS.[52]

At a follow-up time of 17.6 months, OS was significantly improved in the nivolumab group compared with the chemotherapy group (median OS, 10.9 months [95% CI, 9.2–13.3] vs. 8.4 months [95% CI, 7.2–9.9]) (HRdeath, 0.77; 95% CI, 0.62–0.96; P = .019).[52][Level of evidence A1]

Sources: 52 · Level of evidence A1

Grade 3 or 4 treatment-related adverse events occurred in 38 of 209 patients (18%) in the nivolumab group and 131 of 208 patients (63%) in the chemotherapy group.

The most frequent grade 3 or 4 treatment-related adverse events were anemia (4 patients [2%]) in the nivolumab group and decreased neutrophil count (59 patients [28%]) in the chemotherapy group. Five deaths were treatment-related: two in the nivolumab group (one of interstitial lung disease and one of pneumonitis) and three in the chemotherapy group (one of pneumonia, one of spinal cord abscess, and one of interstitial lung disease).

Health professional · Treatment Option Overview for Esophageal Cancer

Postoperative Radiation Therapy

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Two randomized trials have shown no significant OS benefit for postoperative radiation therapy compared with surgery alone.[53,54][Level of evidence A1] All newly diagnosed patients should be considered candidates for therapies and clinical trials comparing various treatment modalities. Information about ongoing clinical trials is available from the NCI website.

Sources: 53 · 54 · Level of evidence A1 · NCI website

Health professional · Treatment Option Overview for Esophageal Cancer

Capecitabine and Fluorouracil Dosing

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[55,56] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[55-57] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[58-60] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[61] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[62]

Sources: 55 · 56 · 55 · 57 · 58 · 60 · 61 · 62

Health professional

Treatment of Stage 0 Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage 0 Esophageal Cancer

Treatment Options for Stage 0 Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Stage 0 squamous cell esophageal cancer is rarely seen in the United States, but surgery has been used. For early-stage minimally invasive esophageal cancer, surgical and endoscopic techniques offer high rates of cure.

Surgery.[1,2]

Sources: Surgery · 1 · 2

Endoscopic resection.[3,4]

Sources: 3 · 4

Health professional

Treatment of Stage I Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage I Esophageal Cancer

Treatment Options for Stage I Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Treatment options for stage I esophageal cancer include:

Chemoradiation therapy followed by surgery.[1-5]

Sources: Chemoradiation therapy followed by surgery · 1 · 5

Surgery alone.[1,3,6,7]

Sources: Surgery alone · 1 · 3 · 6 · 7

Health professional

Treatment of Stage II Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage II Esophageal Cancer

Treatment Options for Stage II Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Treatment options for stage II esophageal cancer include:

Chemoradiation therapy followed by surgery.[1-3]

Sources: Chemoradiation therapy followed by surgery · 1 · 3

Surgery alone.[4-7]

Sources: Surgery alone · 4 · 7

Chemotherapy followed by surgery.[8-10]

Sources: Chemotherapy followed by surgery · 8 · 10

Definitive chemoradiation therapy.[11,12]

Sources: Definitive chemoradiation therapy · 11 · 12

Health professional

Treatment of Stage III Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage III Esophageal Cancer

Treatment Options for Stage III Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Treatment options for stage III esophageal cancer include:

Chemoradiation therapy followed by surgery.[1-3]

Sources: Chemoradiation therapy followed by surgery · 1 · 3

Preoperative chemotherapy followed by surgery.[4-6]

Sources: Preoperative chemotherapy followed by surgery · 4 · 6

Definitive chemoradiation therapy.[7-9]

Sources: Definitive chemoradiation therapy · 7 · 9

Health professional

Treatment of Stage IV Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage IV Esophageal Cancer

Treatment Options for Stage IV Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

At diagnosis, approximately 50% of patients with esophageal cancer have metastatic disease and are candidates for palliative therapy.[1]

Sources: 1

Treatment options for stage IV esophageal cancer include:

Chemoradiation therapy followed by surgery (for patients with stage IVA disease).

Sources: Chemoradiation therapy followed by surgery

Chemotherapy, which has provided partial responses for patients with metastatic distal esophageal adenocarcinomas.[2-4]

Sources: 2 · 4

Adjuvant therapy for patients with completely resected (negative margins) esophageal adenocarcinoma, esophageal squamous cell carcinoma, or gastroesophageal junction cancer who had residual pathologic disease after concurrent chemoradiation therapy.[5]

Sources: Adjuvant therapy for patients with completely resected (negative margins) esophageal adenocarcinoma, esophageal squamous cell carcinoma, or gastroesophageal junction cancer who had residual pathologic disease after concurrent chemoradiation therapy · 5

Immunotherapy and chemoimmunotherapy for patients with previously untreated, unresectable, advanced or metastatic esophageal squamous cell carcinoma.[6-8]

Sources: Immunotherapy and chemoimmunotherapy for patients with previously untreated, unresectable, advanced or metastatic esophageal squamous cell carcinoma · 6 · 8

Immunotherapy and chemoimmunotherapy for patients with previously untreated advanced or metastatic esophageal adenocarcinoma or gastroesophageal junction cancer.[8-10]

Sources: Immunotherapy and chemoimmunotherapy for patients with previously untreated advanced or metastatic esophageal adenocarcinoma or gastroesophageal junction cancer · 8 · 10

Immunotherapy for patients who relapse after one prior line of standard therapy.[11,12]

Sources: Immunotherapy for patients who relapse after one prior line of standard therapy · 11 · 12

Nivolumab and chemotherapy for patients with adenocarcinoma.[9]

Sources: Nivolumab and chemotherapy for patients with adenocarcinoma · 9

Nd:YAG endoluminal tumor destruction or electrocoagulation.[13,14]

Sources: 13 · 14

Endoscopic-placed stents to provide palliation of dysphagia.[15]

Sources: 15

Radiation therapy with or without intraluminal intubation and dilation.

Intraluminal brachytherapy to provide palliation of dysphagia.[16,17]

Sources: 16 · 17

Clinical trials evaluating single-agent or combination chemotherapy.

The treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, inoperable, recurrent, or metastatic esophageal cancer has improved with the introduction of chemoimmunotherapy as front-line therapy and immunotherapy for patients who relapse following one prior line of chemotherapy. First-line chemoimmunotherapy can now be considered the standard of care for patients with advanced esophageal cancer of squamous or adenocarcinoma histology and programmed death-ligand 1 (PD-L1) expression (although the optimal cutoff still needs to be defined). For more information, see the Immunotherapy and Chemoimmunotherapy section.

Sources: Immunotherapy and Chemoimmunotherapy

Health professional

Treatment of Recurrent Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Health professional · Treatment of Recurrent Esophageal Cancer

Treatment Options for Recurrent Esophageal Cancer

Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 21, 2025. Captured 2026-09-09.

Palliation presents difficult problems for all patients with recurrent esophageal cancer. All patients should be considered candidates for clinical trials as outlined in the Treatment Option Overview for Esophageal Cancer section of this summary.

Sources: Treatment Option Overview for Esophageal Cancer

Treatment options for recurrent esophageal cancer include:

Palliative use of any of the other therapies, including supportive care.

Immunotherapy and chemoimmunotherapy for patients with recurrent esophageal squamous cell carcinoma.[1-3]

Sources: Immunotherapy and chemoimmunotherapy for patients with recurrent esophageal squamous cell carcinoma · 1 · 3

For patients

Esophageal Cancer Treatment

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Different types of treatment are available for patients with esophageal cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: clinical trials · research study · standard treatment

Patients have special nutritional needs during treatment for esophageal cancer.

Sources: nutritional

Many people with esophageal cancer find it hard to eat because they have trouble swallowing. The esophagus may be narrowed by the tumor or as a side effect of treatment. Some patients may receive nutrients directly into a vein. Others may need a feeding tube (a flexible plastic tube that is passed through the nose or mouth into the stomach) until they are able to eat on their own.

Sources: esophagus · side effect · nutrients · vein · stomach

The following types of treatment are used:

For patients · Esophageal Cancer Treatment

Surgery

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Surgery

Surgery is the most common treatment for cancer of the esophagus. Part of the esophagus may be removed in an operation called an esophagectomy.

Sources: operation · esophagectomy

The doctor will connect the remaining healthy part of the esophagus to the stomach so the patient can still swallow. A plastic tube or part of the intestine may be used to make the connection. Lymph nodes near the esophagus may also be removed and viewed under a microscope to see if they contain cancer. If the esophagus is partly blocked by the tumor, an expandable metal stent (tube) may be placed inside the esophagus to help keep it open.

Sources: intestine · Lymph nodes · stent

Small, early-stage cancer and high-grade dysplasia of the esophagus may be removed by endoscopic resection. An endoscope (a thin, tube-like instrument with a light and a lens for viewing) is inserted through a small incision (cut) in the skin or through an opening in the body, such as the mouth. A tool attached to the endoscope is used to remove tissue.

Sources: early-stage cancer · high-grade · dysplasia · endoscopic · resection · endoscope

For patients · Esophageal Cancer Treatment

Radiation therapy

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Radiation therapy

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:

Sources: x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: External radiation therapy

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.

Sources: Internal radiation therapy · radioactive · seeds · catheters

The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat esophageal cancer.

A plastic tube may be inserted into the esophagus to keep it open during radiation therapy. This is called intraluminal intubation and dilation.

Sources: intraluminal intubation and dilation

For patients · Esophageal Cancer Treatment

Chemotherapy

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Chemotherapy

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated.

Sources: drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · cavity · abdomen · regional chemotherapy · stage

Learn more at Drugs Approved for Esophageal Cancer.

Sources: Drugs Approved for Esophageal Cancer

For patients · Esophageal Cancer Treatment

Chemoradiation therapy

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Chemoradiation therapy

Chemoradiation therapy combines chemotherapy and radiation therapy to increase the effects of both.

For patients · Esophageal Cancer Treatment

Laser therapy

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Laser therapy

Laser therapy is a cancer treatment that uses a laser beam (a narrow beam of intense light) to kill cancer cells.

For patients · Esophageal Cancer Treatment

Electrocoagulation

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Electrocoagulation

Electrocoagulation is the use of an electric current to kill cancer cells.

For patients · Esophageal Cancer Treatment

Immunotherapy

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Immunotherapy

Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.

Sources: Immunotherapy · immune system

Immune checkpoint inhibitor therapy is a type of immunotherapy being studied to treat patients with advanced esophageal cancer that cannot be removed by surgery and recurrent esophageal cancer. Some types of immune cells, such as T cells, and some cancer cells have certain proteins, called checkpoint proteins, on their surface that keep immune responses in check. When cancer cells have large amounts of these proteins, they will not be attacked and killed by T cells. Immune checkpoint inhibitors block these proteins and the ability of T cells to kill cancer cells is increased.

Sources: Immune checkpoint inhibitor · immune cells · T cells · proteins

There are two types of immune checkpoint inhibitor therapy:

CTLA-4 inhibitor therapy: CTLA-4 is a protein on the surface of T cells that helps keep the body’s immune responses in check. When CTLA-4 attaches to another protein called B7 on a cancer cell, it stops the T cell from killing the cancer cell. CTLA-4 inhibitors attach to CTLA-4 and allow the T cells to kill cancer cells. Ipilimumab is a type of CTLA-4 inhibitor.

Sources: CTLA-4 · Ipilimumab

PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Nivolumab is a type of PD-1 inhibitor.

Sources: PD-1 · Nivolumab

For patients · Esophageal Cancer Treatment

New treatments being tested in clinical trials

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

New treatments being tested in clinical trials

New types of treatment are being tested in clinical trials.

This section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

For patients · Esophageal Cancer Treatment / New treatments being tested in clinical trials

Targeted therapy

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Monoclonal antibody therapy is a type of targeted therapy used in the treatment of esophageal cancer.

Sources: Targeted therapy · Monoclonal antibody

Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.

Sources: antibodies · infusion · toxins · radioactive

For patients · Esophageal Cancer Treatment

Clinical trials

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Clinical trials

Patients may want to think about taking part in a clinical trial.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Clinical trials are taking place in many parts of the country. Find clinical trials for esophageal cancer at Treatment Clinical Trials for Esophageal Cancer. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: Treatment Clinical Trials for Esophageal Cancer · ClinicalTrials.gov

For patients · Esophageal Cancer Treatment

Side effects of treatment

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Side effects of treatment

Treatment for esophageal cancer may cause side effects. For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: Side Effects

For patients · Esophageal Cancer Treatment

Follow-up care

Source: Esophageal Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Follow-up care

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: follow-up

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

Sources: recurred

Studies

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus

NCT00002631 · COMPLETED · phase3

Esophageal Cancer

ClinicalTrials.gov record

Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus

NCT00003118 · COMPLETED · phase3

Esophageal Cancer

ClinicalTrials.gov record

Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer

NCT00047112 · COMPLETED · phase3

Esophageal Cancer

ClinicalTrials.gov record

Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

NCT00416858 · COMPLETED · phase3

Esophageal Cancer

ClinicalTrials.gov record

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

NCT00525785 · COMPLETED · phase2

Stomach Cancer, Gastric Cancer

ClinicalTrials.gov record

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

NCT00861094 · COMPLETED · phase2, phase3

Esophageal Cancer

ClinicalTrials.gov record

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

NCT01196390 · COMPLETED · phase3

Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC...

ClinicalTrials.gov record

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

NCT02509286 · UNKNOWN · phase3

Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)

NCT02559687 · COMPLETED · phase2

Esophageal Carcinoma, Esophagogastric Junction Carcinoma

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

NCT02564263 · COMPLETED · phase3

Esophageal Carcinoma, Esophagogastric Junction Carcinoma

ClinicalTrials.gov record

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

NCT02569242 · COMPLETED · phase3

Esophageal Cancer

ClinicalTrials.gov record

FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer

NCT02581462 · COMPLETED · phase2, phase3

Stomach Cancer, Gastroesophageal Junction Cancer

ClinicalTrials.gov record

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

NCT02872116 · COMPLETED · phase3

Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma

ClinicalTrials.gov record

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

NCT03143153 · COMPLETED · phase3

Various Advanced Cancer

ClinicalTrials.gov record

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

NCT03189719 · COMPLETED · phase3

Esophageal Neoplasms

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

NCT03221426 · COMPLETED · phase3

Gastric Cancer, Gastroesophageal Junction Cancer

ClinicalTrials.gov record

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

NCT03691090 · COMPLETED · phase3

Advanced Esophageal Cancer

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115 · COMPLETED · phase3

Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)

ClinicalTrials.gov record

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147 · ACTIVE NOT RECRUITING · phase3

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

ClinicalTrials.gov record

Evaluations of Alcohol Warning Labels

NCT06129487 · COMPLETED · na

Oral Cancer, Esophageal Cancer, Larynx Cancer, Alcohol Drinking

ClinicalTrials.gov record

Disease and treatment settings

Esophageal Cancer

Disease and treatment setting

Esophageal Cancer

KEYTRUDA QLEX: metastatic Esophageal Cancer with PD-L1 stated without a specific alteration after prior therapy

Disease and treatment setting

1.9 Esophageal Cancer KEYTRUDA QLEX is indicated for the treatment of adult patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma...

KEYTRUDA: metastatic Esophageal Cancer with PD-L1 stated without a specific alteration after prior therapy

Disease and treatment setting

1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not...

OPDIVO QVANTIG: Esophageal Cancer (neoadjuvant) after prior therapy

Disease and treatment setting

1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received...

recurrent Esophageal Cancer

Disease and treatment setting

Treatment of Recurrent Esophageal Cancer

Stage 0 Esophageal Cancer

Disease and treatment setting

Treatment of Stage 0 Esophageal Cancer

Stage I Esophageal Cancer

Disease and treatment setting

Treatment of Stage I Esophageal Cancer

Stage II Esophageal Cancer

Disease and treatment setting

Treatment of Stage II Esophageal Cancer

Stage III Esophageal Cancer

Disease and treatment setting

Treatment of Stage III Esophageal Cancer

Stage IV Esophageal Cancer

Disease and treatment setting

Treatment of Stage IV Esophageal Cancer

TEVIMBRA: unresectable metastatic squamous cell carcinoma with PD-L1 stated without a specific alteration (first-line)

Disease and treatment setting

1 INDICATIONS AND USAGE TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or...

YERVOY: unresectable metastatic squamous cell carcinoma with PD-L1 stated without a specific alteration (first-line)

Disease and treatment setting

1.8 Esophageal Cancer YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1)...

Drug labels

ZIIHERA

Label date 2026-08-24

ZIIHERA is a bispecific HER2-directed antibody indicated for: Gastroesophageal Adenocarcinoma (GEA) • in combination with fluoropyrimidine- and platinum-containing chemotherapy, and tislelizumab-jsgr, as first-line treatment of adult...

DailyMed label